Cystatin C proteoforms in chronic kidney disease

PLoS One. 2023 Feb 1;18(2):e0269436. doi: 10.1371/journal.pone.0269436. eCollection 2023.

Abstract

Cystatin C, a cysteine protease inhibitor, is used as a biomarker of renal function. It offers several advantages compared to creatinine, and formulas for the estimation of the glomerular filtration rate based on cystatin C have been developed. Recently, several proteoforms of cystatin C have been discovered, including an intact protein with a hydroxylated proline at the N-terminus, and N-terminal truncated forms. There is little knowledge about the biological significance of these proteoforms.

Methods: Cross-sectional study of patients with different stages of chronic renal disease (pre-dialysis n = 53; hemodialysis n = 51, renal transplant n = 53). Measurement of cystatin C proteoforms by MALDI-TOF MS, assessment of medicine prescription using the first two levels of the Anatomical Therapeutic chemical system from patients' records.

Results: Patients receiving hemodialysis had the highest cystatin C concentrations, followed by pre-dialysis patients and patients with a renal transplant. In all groups, the most common proteoforms were native cystatin C and CysC 3Pro-OH while the truncated forms made up 28%. The distribution of the different proteoforms was largely independent of renal function and total cystatin C. However, the use of corticosteroids (ATC-L02) and immunosuppressants (ATC-H04) considerably impacted the distribution of proteoforms.

Conclusion: The different proteoforms of cystatin C increased proportionally with total cystatin C in patients with chronic kidney disease. Prescription of corticosteroids and immunosuppressants had a significant effect on the distribution of proteoforms. The biological significance of these proteoforms remains to be determined.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Creatinine / metabolism
  • Cross-Sectional Studies
  • Cystatin C
  • Glomerular Filtration Rate
  • Humans
  • Immunosuppressive Agents
  • Kidney Transplantation*
  • Renal Insufficiency, Chronic* / therapy

Substances

  • Cystatin C
  • Biomarkers
  • Immunosuppressive Agents
  • Creatinine

Grants and funding

HD received a grant from the University of Bergen (no grant number available) www.uib.no. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.